CADENCE PHARMACEUTICALS INC
Period
FY 2013
Revenue
$112.56M
Net Income
$-24.29M
Total Assets
$90.80M
Equity
$34.88M
Shares Out
89.18M
Op. Cash Flow
$-23.19M
Business
CADENCE PHARMACEUTICALS INC is a former operating company in Pharmaceutical Preparations. Securities are no longer actively traded on a major U.S. exchange.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2013 2013-12-31 | FY 2012 2012-12-31 | FY 2011 2011-12-31 | FY 2010 2010-12-31 | FY 2009 2009-12-31 |
|---|---|---|---|---|---|---|
| Product revenue, net | 111 | 50 | 11 | — | — | |
| License revenue | 2 | 118,000 | 5 | — | — | |
| Total net revenues | 113 | 50 | 17 | — | — | |
| Cost of product sales | 38 | 23 | 12 | — | — | |
| Amortization of patent license | 1 | 1 | 2 | — | — | |
| Research and development | 7 | 7 | 9 | 14 | 19 | |
| Selling, general and administrative | 94 | 87 | 82 | 39 | 25 | |
| Impairment of long-lived assets | — | 8 | — | 2 | — | |
| Other | −441,000 | 1 | 1 | — | — | |
| Total costs and expenses | 140 | 127 | 105 | 55 | 44 | |
| Loss from operations | −28 | −77 | −89 | −55 | −44 | |
| Interest income | 69,000 | 123,000 | 136,000 | 106,000 | 182,000 | |
| Interest expense | −4 | −4 | −4 | −2 | −1 | |
| Other income | 8 | 27,000 | 9,000 | 312,000 | −39,000 | |
| Total other income (expense), net | 3 | −4 | −4 | −2 | −994,000 | |
| Loss before income tax | −24 | −81 | −93 | −57 | −45 | |
| Net loss | −24 | −81 | −93 | −57 | −45 | |
| Basic and diluted net loss per share | −0.28 | −0.95 | −1.41 | −1.09 | −0.93 | |
| Shares used to compute basic and diluted net loss per share | 86 | 86 | 66 | 52 | 49 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2013 2013-12-31 | FY 2012 2012-12-31 | FY 2011 2011-12-31 | FY 2010 2010-12-31 | FY 2009 2009-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 55 | 58 | 83 | 112 | 76 | |
| Investments in marketable securities | 2 | 4 | 45 | 22 | — | |
| Restricted cash | 548,000 | 640,000 | 450,000 | 150,000 | — | |
| Accounts receivable, net | 9 | 6 | 2 | — | — | |
| Inventory | 9 | 6 | 1 | 485,000 | — | |
| Prepaid expenses | 2 | 1 | 1 | 1 | — | |
| Other current assets | 91,000 | 90,000 | 90,000 | 36,000 | — | |
| Total current assets | 78 | 77 | 132 | 136 | — | |
| Property and equipment, net | 2 | 2 | 11 | 9 | — | |
| Intangible assets, net | 11 | 12 | 13 | 15 | — | |
| Restricted cash | 92,000 | — | 190,000 | 190,000 | — | |
| Other assets | 16,000 | 7 | 7 | 4 | — | |
| Total assets | 91 | 98 | 164 | 164 | — | |
| Accounts payable | 8 | 6 | 4 | 3 | — | |
| Accrued liabilities | 18 | 13 | 10 | 7 | — | |
| Deferred revenue | — | 2 | 1 | — | — | |
| Current portion of long-term debt, less discount of $252 and $-, respectively | 11 | — | — | 4 | — | |
| Total current liabilities | 37 | 21 | 16 | 15 | — | |
| Long-term debt, less discount of $433 and $1,182, respectively | 19 | 29 | 29 | 25 | — | |
| Other long-term liabilities | 844,000 | 51,000 | 117,000 | 447,000 | — | |
| Total liabilities | 56 | 50 | 44 | 40 | — | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2013 and 2012, respectively | — | — | — | — | — | |
| Common stock, $0.0001 par value; 200,000,000 shares authorized, 86,719,716 shares and 85,668,668 shares issued and outstanding at December 31, 2013 and 2012, respectively | 9,000 | 9,000 | 9,000 | 6,000 | — | |
| Additional paid-in capital | 507 | 495 | 486 | 398 | — | |
| Accumulated other comprehensive income | — | — | 2,000 | — | — | |
| Accumulated deficit | −472 | −448 | −367 | −274 | — | |
| Total stockholders' equity | 35 | 48 | 119 | 124 | 75 | |
| Total liabilities and stockholders' equity | 91 | 98 | 164 | 164 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2013 2013-12-31 | FY 2012 2012-12-31 | FY 2011 2011-12-31 | FY 2010 2010-12-31 | FY 2009 2009-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 213,000 | 2 | 2 | 758,000 | 537,000 | |
| Loss (gain) on disposal of assets | — | 873,000 | −66,000 | 55,000 | 7,000 | |
| Gain on sale of investment | −8 | — | — | — | — | |
| Inventory write-down | 0 | 163,000 | 6 | — | — | |
| Stock-based compensation | 7 | 9 | 9 | 11 | 8 | |
| Non-cash interest expense | 17,000 | 27,000 | 49,000 | — | — | |
| Amortization of discount on note payable | 497,000 | 122,000 | 409,000 | 373,000 | 219,000 | |
| Accretion of discounts on available-for-sale securities, net of accretion of premiums | −1,000 | −16,000 | 5,000 | 29,000 | 130,000 | |
| Accounts receivable | −3 | −4 | −2 | — | — | |
| Prepaid expenses and other assets | −830,000 | −78,000 | 104,000 | −585,000 | −444,000 | |
| Inventory | −2 | −5 | −6 | −485,000 | — | |
| Accounts payable | 2 | 2 | 360,000 | 653,000 | −2 | |
| Deferred revenue | −2 | 943,000 | 1 | — | — | |
| Accrued liabilities and other liabilities | 6 | 2 | 3 | −82,000 | −3 | |
| Net cash used in operating activities | −23 | −64 | −78 | −59 | −42 | |
| Purchases of marketable securities | — | −1 | −83 | −24 | −11 | |
| Maturities and sales of marketable securities | 1 | 42 | 60 | — | — | |
| Payment for option purchase right | — | — | −4 | −4 | — | |
| Proceeds from the sale of Incline options and preferred shares | 15 | — | — | — | — | |
| Restricted cash | — | — | −300,000 | 1 | 1 | |
| Purchases of property and equipment | −505,000 | −2 | −3 | −4 | −3 | |
| Proceeds from the sale of property and equipment | 80,000 | 393,000 | 66,000 | 3,000 | — | |
| Net cash provided by (used in) investing activities | 16 | 40 | −29 | −22 | −8 | |
| Proceeds from issuance of common stock | 4 | 451,000 | 79 | 94 | 86 | |
| Borrowings under debt agreements, net of fees | — | — | 3 | 30 | — | |
| Principal payments under debt agreements | — | — | −4 | −6 | −8 | |
| Net cash provided by financing activities | 4 | 451,000 | 78 | 117 | 79 | |
| Net decrease in cash and cash equivalents | −3 | −24 | −30 | 36 | 28 | |
| Issuance of warrants in connection with loan and security agreement | — | 416,000 | 390,000 | 1 | — | |
| Property and equipment purchases in accounts payable and accrued expenses | 232,000 | 338,000 | 891,000 | 371,000 | 1 | |
| Cash paid for interest and fees | 3 | 4 | 4 | 2 | 814,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is CADENCE PHARMACEUTICALS INC's CIK number?
CADENCE PHARMACEUTICALS INC's SEC CIK number is 0001333248 (1333248). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CADENCE PHARMACEUTICALS INC's SEC filings?
All of CADENCE PHARMACEUTICALS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.